Eliana Clark - Mar 1, 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, Chief Technical Officer
Signature: James Basta, attorney-in-fact
Stock symbol: NTLA
Transactions as of: Mar 1, 2025
Transactions value $: -$6,104
Form type: 4
Date filed: 3/4/2025, 04:43 PM
Previous filing: Jan 6, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Award	$0	+32K	+49.96%	$0.00	96K	Mar 1, 2025	Direct	F1
transaction	NTLA	Common Stock	Sale	-$6.1K	-679	-0.71%	$8.99	95.4K	Mar 4, 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock Option (right to buy)	Award	$0	+45.7K		$0.00	45.7K	Mar 1, 2025	Common Stock	45.7K	$10.09	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2	Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2025, and does not represent a volitional trade by the Reporting Person.
F3	This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.